Many political leaders increasingly view regulatory exclusivity as a lucrative handout to pharmaceutical companies. In a new DC Journal op-ed, Professor Kristina M. L. Acri née Lybecker explains why that narrative is mistaken -- and cautions against policies that would weaken exclusivity and discourage the investments that lead to new medicines.
"It's vital for policymakers to understand that regulatory exclusivity isn't a windfall or a loophole. It is a load-bearing incentive for medical innovation and all the societal benefits it delivers, from improved longevity and worker productivity, to reduced spending on hospital care, to more research and manufacturing jobs."
Read the full op-ed here.